ÂÜÀòÂÒÂ×

Carmen Bozic, M.D., joined Vertex in 2019 and is the company’s Executive Vice President of Global Medicines Development and Medical Affairs (GMDA), and Chief Medical Officer. In this role, Dr. Bozic oversees clinical development, medical affairs, drug safety, global clinical operations, biometrics, and other related functions and is responsible for developing and driving execution of Vertex’s clinical development programs.

Prior to Vertex, Dr. Bozic spent more than 20 years at Biogen where she held positions of increasing responsibility, including as Senior Vice President of Global Development, an organization of more than 500 people in the US, Europe and Japan. During her tenure at Biogen, she led multiple functions including Global Clinical Development, Safety, Preclinical Safety, Regulatory, Clinical Operations and Biometrics. She has deep experience leading global clinical development programs across all phases of development, as well as multiple diseases and therapeutic modalities. Dr. Bozic has overseen the development, regulatory filings and approvals of several therapies, including TYSABRI® (natalizumab), AVONEX® (interferon beta-1a) pre-filled syringe and auto-injector, FAMPYRA® (fampridine), TECFIDERA® (dimethyl fumarate), PLEGRIDY® (pegylated interferon beta-1a), and ZINBRYTA® (daclizumab) for the treatment of multiple sclerosis; ELOCTATE® (Factor VIII Fc fusion protein) and ALPROLIX® (Factor IX Fc fusion protein) for the treatment of severe Hemophilia A and B; and SPINRAZA® (nusinersen) for the treatment of spinal muscular atrophy.

Dr. Bozic was the industry representative to the FDA’s Risk Communication Advisory Committee and was a member of PhRMA’s Clinical and Preclinical Development Committee. She is a member of the Clinical Advisory Committee at Akili Interactive. She received her medical degree from McGill University, where she also completed her residency in internal medicine and served as Chief Resident. She also completed a combined fellowship in Pulmonary and Critical Care Medicine at Brigham and Women’s and Beth Israel Deaconess Hospital. Dr. Bozic conducted research at the Ina Sue Perlmutter Cystic Fibrosis Research Laboratory at Boston Children’s Hospital, focusing on the role of chemokines and neurokinins in inflammatory responses. She was an Associate Physician at Beth Israel Deaconess Medical Center and Harvard Medical School before joining the biopharmaceutical industry.